MonoSol Rx gets IPR against Arius Two's US Patent No. 7,579,019
From a press release:
WARREN, N.J., Oct. 6, 2014 (GLOBE NEWSWIRE) -- The United States Patent and Trademark Office (USPTO) has granted MonoSol Rx, LLC's (MonoSol Rx) petition for inter partes review (IPR) of all claims of US Patent No. 7,579,019 ("the '019 patent") and has instituted the IPR. The '019 patent, owned by Arius Two, Inc, a wholly-owned subsidiary of BioDelivery Sciences International, Inc. (Nasdaq:BDSI) ("BDSI"), is cited by BDSI as a key patent in their BEMA drug delivery technology.